Phase 1 Prostate Cancer Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• Adults between 18 and 75 years old (inclusive)
• People who have at least one measurable area of cancer that can be tracked during the trial
• People in the Phase Ia part (Cohort A): those with an advanced solid tumour that has a specific DNA repair gene change (called an HRR gene mutation), where standard treatments have stopped working, caused intolerable side effects, or are not available to them
• People in the Phase Ib part may join one of several groups based on their cancer type: recurrent ovarian cancer with a specific DNA repair deficiency (HRD positive); advanced HER2-negative breast cancer with an HRR gene mutation; advanced pancreatic cancer with an HRR gene mutation; advanced prostate cancer that no longer responds to hormone treatment (mCRPC) with an HRR gene mutation; colorectal cancer with an HRR gene mutation; or other advanced solid tumours with an HRR gene mutation or HRD positive result — in all cases, where standard treatments have stopped working, caused intolerable side effects, or are not available
• People who are generally well enough to carry out light activity and care for themselves (rated 0 or 1 on a standard cancer fitness scale)
• People with a life expectancy of more than 12 weeks
• Women who are not breastfeeding and who are using reliable contraception; men who are also using reliable contraception
• People who have read and signed the trial's informed consent form

Who may not be able to join:

• People who have previously been treated with two or more PARP inhibitor medicines (a type of targeted cancer drug)
• People who have received traditional Chinese medicine used for tumours within 2 weeks before starting the trial
• People who have received standard chemotherapy, another experimental drug, or other systemic cancer treatments within 3 weeks before starting; or certain specific chemotherapy drugs (Nitrosourea or Mitomycin C) within 6 weeks before starting
• People who have had localised radiation therapy within 2 weeks before starting, or radiation covering a large area of bone marrow within 4 weeks before starting
• People who have fluid build-up around the lungs or abdomen requiring medical treatment, or fluid around the heart
• People who have had major surgery within 4 weeks before starting the trial
• People still experiencing significant side effects (grade 2 or higher) from previous cancer treatments
• People who have had another separate primary cancer in the past
• People with cancer that has spread to the brain or spinal cord that is untreated or currently active
• People with poor bone marrow function, or liver or kidney function that does not meet the trial's requirements (confirm with trial site)
• People with certain blood or bone marrow conditions, including myelodysplastic syndrome (MDS) or acute myeloid leukaemia (AML), or signs suggesting these conditions
• People with severe, uncontrolled, or active heart or blood vessel problems
• People who have had a serious blood sugar crisis (diabetic ketoacidosis or hyperosmolar hyperglycaemic state) within 6 months before starting, or whose long-term blood sugar control measure (HbA1c) is 7.5% or higher
• People with serious or poorly controlled high blood pressure
• People who have had a life-threatening bleeding event, or needed a blood transfusion, within the 120 days before starting; or who currently have significant or ongoing bleeding
• People who have had a serious infection within 4 weeks before starting, or who have an active uncontrolled infection at the time of screening
• People with serious neurological or psychiatric conditions
• People with a known allergy or sensitivity to the trial drug (HS-10502) or to closely related drugs
• People who the trial doctors believe are unlikely to follow the trial procedures reliably
• People with any other condition that the trial doctors believe could affect their safety or the reliability of the trial results

Important: Always verify eligibility with the trial site directly before applying.